Cardinal Health (NYSE:CAH) CEO Sells 7,354 Shares

Key Points

• CEO Deborah Weitzman sold 7,354 Cardinal Health shares at an average price of $235.45, generating approximately $1.73 million. The sale reduced her ownership by 8.63%, leaving her with 77,901 shares.
• Cardinal Health reported quarterly EPS of $2.91, beating estimates by $0.49, while revenue rose 5.8% year over year to $63.67 billion. The company reaffirmed fiscal 2027 EPS guidance of $12.40–$12.60.
• The company declared a quarterly dividend of $0.5158 per share, representing a 0.9% annualized yield. Analysts maintain a consensus “Moderate Buy” rating with an average price target of $266.56.

Cardinal Health, Inc. (NYSE:CAH - Get Free Report) CEO Deborah Weitzman sold 7,354 shares of the company's stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $235.45, for a total transaction of $1,731,499.30. Following the transaction, the chief executive officer owned 77,901 shares in the company, valued at $18,341,790.45. The trade was a 8.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Cardinal Health Price Performance

Shares of Cardinal Health stock opened at $234.73 on Thursday. The firm has a 50 day simple moving average of $231.76 and a 200 day simple moving average of $217.68. Cardinal Health, Inc. has a fifty-two week low of $145.87 and a fifty-two week high of $258.30. The firm has a market cap of $54.59 billion, a P/E ratio of 32.47, a P/E/G ratio of 1.26 and a beta of 0.49.

Cardinal Health (NYSE:CAH - Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported $2.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.42 by $0.49. The firm had revenue of $63.67 billion for the quarter, compared to the consensus estimate of $65.15 billion. Cardinal Health had a negative return on equity of 98.53% and a net margin of 0.67%.The business's revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.08 EPS. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. On average, sell-side analysts expect that Cardinal Health, Inc. will post 12.54 EPS for the current year.

Cardinal Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Thursday, October 1st will be issued a $0.5158 dividend. The ex-dividend date is Thursday, October 1st. This represents a $2.06 annualized dividend and a yield of 0.9%. Cardinal Health's dividend payout ratio (DPR) is currently 28.49%.

Hedge Funds Weigh In On Cardinal Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Sigma Planning Corp grew its position in shares of Cardinal Health by 31.4% during the 2nd quarter. Sigma Planning Corp now owns 14,126 shares of the company's stock worth $3,356,000 after buying an additional 3,379 shares during the period. Two Sigma Securities LLC acquired a new stake in shares of Cardinal Health in the 2nd quarter valued at approximately $4,919,000. Benjamin Edwards Inc. boosted its stake in Cardinal Health by 18.6% during the 2nd quarter. Benjamin Edwards Inc. now owns 9,136 shares of the company's stock worth $2,170,000 after acquiring an additional 1,435 shares during the last quarter. Flputnam Investment Management Co. grew its holdings in Cardinal Health by 0.8% during the second quarter. Flputnam Investment Management Co. now owns 70,728 shares of the company's stock valued at $16,802,000 after purchasing an additional 535 shares during the period. Finally, Cookson Peirce & Co. Inc. grew its holdings in Cardinal Health by 0.4% during the second quarter. Cookson Peirce & Co. Inc. now owns 227,784 shares of the company's stock valued at $54,112,000 after purchasing an additional 963 shares during the period. Institutional investors own 87.17% of the company's stock.

Analyst Ratings Changes

A number of research firms have issued reports on CAH. JPMorgan Chase & Co. upped their target price on shares of Cardinal Health from $215.00 to $260.00 and gave the company a "neutral" rating in a research report on Thursday, August 13th. Barclays boosted their price target on shares of Cardinal Health from $258.00 to $275.00 and gave the stock an "overweight" rating in a research note on Thursday, August 13th. UBS Group increased their price objective on shares of Cardinal Health from $274.00 to $280.00 and gave the company a "buy" rating in a report on Wednesday, August 12th. Robert W. Baird raised their price objective on shares of Cardinal Health from $251.00 to $274.00 and gave the company an "outperform" rating in a research note on Wednesday, August 12th. Finally, Zacks Research lowered shares of Cardinal Health from a "strong-buy" rating to a "hold" rating in a report on Friday, June 12th. Sixteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Cardinal Health currently has a consensus rating of "Moderate Buy" and an average target price of $266.56.

About Cardinal Health

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company's core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source